Diamedica Inc (DMCAF) 0.0820 $DMCAF
Avivagen Announces Two Appointments to its Board of Directors, Mr. David Allan and Ms. Vanessa Grant
ACCESSWIRE - Thu May 14, 6:34AM CDT
OTTAWA, ON/ ACCESSWIRE / May 14 2015 / Avivagen Inc. (TSXV:VIV, PINKSHEETS:CHEXF), a life sciences company that develops and delivers products that support and enhance the health of livestock, pets and people, announces the appointment of two new Directors, Mr. David Allan and Ms. Vanessa Grant, and the resignation of two past Directors, Dr. Janusz Daroszewski and Dr. Chandra Panchal.
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 391.24 (-3.11), ACOR: 30.04 (+0.14), GSK: 44.77 (-0.22), AZN: 69.29 (-0.81), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04)
DiaMedica to Present at the 12th Annual BIO Asia International Conference
Marketwired - Thu Mar 19, 9:20AM CDT
DiaMedica Inc. (TSX VENTURE: DMA) today, announced that the Company has been selected to present at the 12th Annual BIO Asia International Conference on March 24th, 2015 at 4:30 PM JST (UTC+9) at the Grand Hyatt Hotel in Tokyo, Japan. DiaMedica will be providing an overview of the expanded focus of DM199, a naturally occurring form of tissue kallikrein-1, into acute vascular diseases with an initial focus on acute ischemic stroke.
DMA.VN: 0.145 (+0.040)
DiaMedica Completes Non-Brokered Private Placement
Marketwired - Mon Mar 16, 7:53AM CDT
DiaMedica Inc. (the "Company"
(TSX VENTURE: DMA), announced today, further to its news release of February 27, 2015, the closing of its non-brokered private placement raising total gross proceeds of $600,000 (the "private placement" . The proceeds will be used by DiaMedica to support development with DM199 for the treatment of vascular diseases and for other working capital purposes.
DMA.VN: 0.145 (+0.040)
DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases
Marketwired - Mon Feb 02, 7:31AM CST
DiaMedica Inc. (TSX VENTURE: DMA) today, announced that the company will pursue the development of DM199, its recombinant form of the naturally occurring protein, tissue kallikrein-1 in acute vascular disease of the brain, kidney and heart. The primary focus will be on acute ischemic stroke and acute kidney injury indications.
DMA.VN: 0.145 (+0.040)
DiaMedica Announces Resignation of Mark Robbins, as Executive Vice President
Marketwired - Tue Jan 20, 7:15AM CST
DiaMedica Inc. (TSX VENTURE: DMA) announced today that Mark Robbins has resigned his position with the Company to pursue other opportunites. Mark joined DiaMedica as Vice President of Clinical and Regulatory and was named Executive Vice President in July 2014.
DMA.VN: 0.145 (+0.040)
DiaMedica Appoints David Gurvey as Vice President of Finance
Marketwired - Thu Jan 15, 7:04AM CST
DiaMedica Inc. (TSX VENTURE: DMA) today announced the appointment of Mr. David Gurvey as the Company's Vice President of Finance. Mr. Gurvey has more than 13 years of experience working with publicly traded and private companies in senior financial roles.
DMA.VN: 0.145 (+0.040)
DiaMedica Announces Restructuring
Marketwired - Tue Dec 09, 5:31PM CST
DiaMedica Inc. (TSX VENTURE: DMA) today announced a company-wide restructuring aimed at preserving cash, reducing operating costs and re-positioning the Company going forward.
DMA.VN: 0.145 (+0.040)
DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes
Marketwire Canada - Mon Nov 17, 7:00AM CST
DiaMedica Inc. (TSX VENTURE
MA) today announced top-line results of its Phase IIa proof of concept clinical trial of DM199 in patients with type 2 diabetes. DM199 is a recombinant form of the human tissue kallikrein-1 protein (rhKLK1).
DMA.VN: 0.145 (+0.040)
DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
Marketwire - Thu Aug 07, 7:05AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced the publication of its manuscript entitled, "Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus," in PLOS ONE, an international, peer-reviewed, open access, scientific journal. The manuscript can be accessed at http://dx.plos.org/10.1371/journal.pone.0103981.
DMA.VN: 0.145 (+0.040)
DiaMedica to Present at InvestMNt Conference on August 6, 2014
Marketwire - Wed Jul 30, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota.
DMA.VN: 0.145 (+0.040)
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
Marketwire - Fri Jul 25, 3:30PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced that at its Annual General and Special Meeting (the "Meeting" of shareholders held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson Reimer and Thomas Wellner were re-elected as the Company's board of directors.
DMA.VN: 0.145 (+0.040)
Avivagen Announces Two Appointments to its Board of Directors, Mr. David Allan and Ms. Vanessa Grant
ACCESSWIRE - Thu May 14, 6:34AM CDT
OTTAWA, ON/ ACCESSWIRE / May 14 2015 / Avivagen Inc. (TSXV:VIV, PINKSHEETS:CHEXF), a life sciences company that develops and delivers products that support and enhance the health of livestock, pets and people, announces the appointment of two new Directors, Mr. David Allan and Ms. Vanessa Grant, and the resignation of two past Directors, Dr. Janusz Daroszewski and Dr. Chandra Panchal.
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 391.24 (-3.11), ACOR: 30.04 (+0.14), GSK: 44.77 (-0.22), AZN: 69.29 (-0.81), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04)
DiaMedica to Present at the 12th Annual BIO Asia International Conference
Marketwired - Thu Mar 19, 9:20AM CDT
DiaMedica Inc. (TSX VENTURE: DMA) today, announced that the Company has been selected to present at the 12th Annual BIO Asia International Conference on March 24th, 2015 at 4:30 PM JST (UTC+9) at the Grand Hyatt Hotel in Tokyo, Japan. DiaMedica will be providing an overview of the expanded focus of DM199, a naturally occurring form of tissue kallikrein-1, into acute vascular diseases with an initial focus on acute ischemic stroke.
DMA.VN: 0.145 (+0.040)
DiaMedica Completes Non-Brokered Private Placement
Marketwired - Mon Mar 16, 7:53AM CDT
DiaMedica Inc. (the "Company"
(TSX VENTURE: DMA), announced today, further to its news release of February 27, 2015, the closing of its non-brokered private placement raising total gross proceeds of $600,000 (the "private placement" . The proceeds will be used by DiaMedica to support development with DM199 for the treatment of vascular diseases and for other working capital purposes. DMA.VN: 0.145 (+0.040)
DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases
Marketwired - Mon Feb 02, 7:31AM CST
DiaMedica Inc. (TSX VENTURE: DMA) today, announced that the company will pursue the development of DM199, its recombinant form of the naturally occurring protein, tissue kallikrein-1 in acute vascular disease of the brain, kidney and heart. The primary focus will be on acute ischemic stroke and acute kidney injury indications.
DMA.VN: 0.145 (+0.040)
DiaMedica Announces Resignation of Mark Robbins, as Executive Vice President
Marketwired - Tue Jan 20, 7:15AM CST
DiaMedica Inc. (TSX VENTURE: DMA) announced today that Mark Robbins has resigned his position with the Company to pursue other opportunites. Mark joined DiaMedica as Vice President of Clinical and Regulatory and was named Executive Vice President in July 2014.
DMA.VN: 0.145 (+0.040)
DiaMedica Appoints David Gurvey as Vice President of Finance
Marketwired - Thu Jan 15, 7:04AM CST
DiaMedica Inc. (TSX VENTURE: DMA) today announced the appointment of Mr. David Gurvey as the Company's Vice President of Finance. Mr. Gurvey has more than 13 years of experience working with publicly traded and private companies in senior financial roles.
DMA.VN: 0.145 (+0.040)
DiaMedica Announces Restructuring
Marketwired - Tue Dec 09, 5:31PM CST
DiaMedica Inc. (TSX VENTURE: DMA) today announced a company-wide restructuring aimed at preserving cash, reducing operating costs and re-positioning the Company going forward.
DMA.VN: 0.145 (+0.040)
DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes
Marketwire Canada - Mon Nov 17, 7:00AM CST
DiaMedica Inc. (TSX VENTURE
MA) today announced top-line results of its Phase IIa proof of concept clinical trial of DM199 in patients with type 2 diabetes. DM199 is a recombinant form of the human tissue kallikrein-1 protein (rhKLK1). DMA.VN: 0.145 (+0.040)
DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
Marketwire - Thu Aug 07, 7:05AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced the publication of its manuscript entitled, "Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus," in PLOS ONE, an international, peer-reviewed, open access, scientific journal. The manuscript can be accessed at http://dx.plos.org/10.1371/journal.pone.0103981.
DMA.VN: 0.145 (+0.040)
DiaMedica to Present at InvestMNt Conference on August 6, 2014
Marketwire - Wed Jul 30, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota.
DMA.VN: 0.145 (+0.040)
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
Marketwire - Fri Jul 25, 3:30PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced that at its Annual General and Special Meeting (the "Meeting"
of shareholders held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson Reimer and Thomas Wellner were re-elected as the Company's board of directors. DMA.VN: 0.145 (+0.040)
